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In the first issue of Volume 134 of Acta Neuropathologica, we reported the substantial accumulation 26 
of abnormal deposits of superoxide dismutase 1 (SOD1) protein in the idiopathic Parkinson’s disease 27 
brain, reflecting the pattern of neuronal loss in this disorder more closely than that of -synuclein 28 
[10]. We presented evidence of catalytically dysfunctional, misfolded conformations of soluble and 29 
aggregated SOD1 protein in degenerating Parkinson’s disease brain regions, similar to neurotoxic 30 
SOD1 proteinopathy in the spinal cord [8] and substantia nigra pars compacta (SNc) of familial 31 
amyotrophic lateral sclerosis (fALS) patients with mutations in the SOD1 gene. Comparable changes 32 
in SOD1 structure and function suggest a common biochemical pathway contributing to neuron loss 33 
in both disorders. This provokes the question of whether mutant SOD1 is a feature of Parkinson’s 34 
disease.   35 
In the time since our report was published, we have conducted genotyping experiments on the 17 36 
idiopathic Parkinson’s disease cases in which we observed SOD1 dysfunction and aggregation to 37 
identify possible mutations in SOD1, using our previously reported methods for genetic profiling of 38 
SOD1 in fALS [7]. No sequence variations from wild type SOD1 were identified in any of these cases 39 
of Parkinson’s disease. This finding is consistent with the single study reported to date that failed to 40 
identify SOD1 mutations in index familial Parkinson’s disease patients representing 23 genealogies 41 
[1]. One participant in our Parkinson’s disease cohort possessed a known intronic deletion found in 42 
healthy individuals (dbSNP rs398081559, c.573+88 del A), but did not represent an outlier within our 43 
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published datasets for SOD1 misfolding and deposition [10]. The absence of mutations in SOD1 in 1 
our Parkinson’s disease cohort indicates that aggregated SOD1 in these cases is wild type protein.  2 
This negative result is important, as it demonstrates that wild-type, and mutant, SOD1 can express 3 
comparable dysfunctional activities and abnormal conformations in Parkinson’s disease and fALS, 4 
respectively. These perturbations may represent a common basis for neuronal vulnerability in these 5 
disorders through a common molecular pathway that may involve either wild type or mutant SOD1.   6 
The formation of a thermally stable SOD1 homodimer is essential for catalytic dismutation of 7 
superoxide to hydrogen peroxide and oxygen, mediated by two copper (II) ions. The binding of these 8 
copper (II) ions, along with the binding of two zinc (II) ions and the formation of an intramonomeric 9 
metal-stabilised disulfide bridge (Cys57-Cys146), affords the protein its exceptional thermodynamic 10 
stability. Consequently, reduced copper binding to SOD1 results in a profound destabilization of the 11 
protein and simultaneously prevents the permanent formation of the stabilizing intramonomeric 12 
disulfide bridge and the catalysis of superoxide [6]. Modification of any one of the protein’s four 13 
cysteine residues [9], or tyrosine or histidine residues [11], can also result in an unstable protein 14 
prone to disordered oligomerisation. In cases of SOD1 fALS , such perturbations may be attributable 15 
to the mutated protein but our current data indicate that, in idiopathic Parkinson’s disease, such 16 
modifications occur following normal protein translation. Abnormal post-translational modifications 17 
of the wild type protein likely arise from a combination of substantially elevated intraneuronal 18 
oxidative stress and biometal dyshomeostasis characteristic of degenerating brain regions in 19 
Parkinson’s disease [3, 10]. Importantly, despite a lack of concrete evidence of misfolded SOD1 in 20 
the more prevalent sporadic form of (s)ALS [2], these results support data demonstrating atypical 21 
post-translational modification of wild type SOD1 which may result in SOD1 dysfunction in sALS 22 
comparable to mutant SOD1 dysfunction in SOD1 fALS [4].  23 
In summary, we propose that a copper deficiency in SOD1, arising from either SOD1 mutations that 24 
affect metal binding in fALS [5], or the generalised paucity of copper within catecholaminergic 25 
neurons we have previously reported in the Parkinson’s disease brain [3], is directly associated with 26 
SOD1 misfolding and dysfunction [10]. The absence of mutations to SOD1 in our Parkinson’s disease 27 
cohort further justifies the conclusions we drew in our recent paper in Acta Neuropathologica; that a 28 
key endogenous mediator of oxidative stress in vulnerable catecholaminergic neurons is not only 29 
defective due to a lack of bioavailable copper, but is also susceptible to detrimental modifications 30 
that further impair metal retention, resulting in neurotoxic aggregation. This has important 31 
implications for the search for a tractable molecular ‘trigger’ of neurodegeneration in Parkinson’s 32 
disease, but also for a potential role of wild type SOD1 dysfunction in sALS.  33 
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